Impact of Thromboprophylaxis Intensity on Patients' Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study

被引：2

作者：

Almohareb, Sumaya N. ^{[1
,2
,3
]}

Al Yami-, Majed S. ^{[1
,2
,3
]}

Assiri, Ahmed M. ^{[4
]}

Almohammed, Omar A. ^{[5
,6
]}

机构：

[1] King Saud bin Abdulaziz Univ Hlth Sci, Coll Pharm, Dept Pharm Practice, Riyadh, Saudi Arabia

[2] King Abdul Aziz Med City, Dept Clin Pharm, Riyadh, Saudi Arabia

[3] King Abdullah Int Med Res Ctr, Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia

[4] Minist Hlth, Hlth Volunteering Ctr, Riyadh, Saudi Arabia

[5] King Saud Univ, Coll Pharm, Dept Clin Pharm, POB 2457, Riyadh 11451, Saudi Arabia

[6] King Saud Univ, Coll Pharm, Pharmacoecon Res Unit, Riyadh, Saudi Arabia

来源：

CLINICAL EPIDEMIOLOGY | 2022年 / 14卷

关键词：

COVID-19; venous thromboembolism; anticoagulation; thromboprophylaxis; mortality; VENOUS THROMBOEMBOLISM; ANTICOAGULATION;

D O I：

10.2147/CLEP.S359132

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Purpose: Venous thromboembolism (VTE), a major complication that has been reported in patients with COVID-19, is associated with an increased risk of mortality. The purpose of this study was to compare in-hospital mortality among hospitalized patients with COVID-19 who received high-intensity versus standard-intensity thromboprophylactic anticoagulation. Patients and Methods: A secondary database analysis was conducted using data for adult patients who were hospitalized for COVID-19 in Saudi Arabia and received enoxaparin for thromboprophylaxis during their hospitalization. While enoxaparin 40 mg daily is considered the standard-intensity, doses higher than the standard but not to reach the therapeutic dose were considered as high-intensity. The primary outcome in the study was in-hospital mortality, and the secondary outcomes included intensive care unit (ICU) and hospital length of stay. Chi-square and t-tests were used to assess the difference between the two independent groups, and propensity score matching was performed to adjust for baseline characteristics. Results: From 3508 patients who received high- or standard-intensity enoxaparin, 1422 patients, 711 in each group, were included in the analyses after propensity score matching. The mean age of the participants was 57.2 years, and around 30% of them were female. About 72% of the patients were admitted to the ICU. No difference was observed between the two groups in the in-hospital mortality outcome (36% vs 33.5% in the high-intensity and the standard group, respectively; RR=1.06, 95% CI 0.95-1.18). However, patients who received high-intensity thromboprophylaxis had a significantly longer duration of hospitalization (15.6 days vs 13.6 days; p=0.003) and ICU stay (12.3 days vs 10.8 days; p=0.039) compared to patients who received the standard dose. Conclusion: The use of high-intensity thromboprophylaxis was not associated with a reduction in mortality. Therefore, our results do not support the routine use of high-intensity prophylactic anticoagulation in both ICU and non-ICU patients with COVID-19.

引用

页码：361 / 368

页数：8

共 32 条

[1] Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19 [J].

Al-Samkari, Hanny ;

Gupta, Shruti ;

Leaf, Rebecca Karp ;

Wang, Wei ;

Rosovsky, Rachel P. ;

Brenner, Samantha K. ;

Hayek, Salim S. ;

Berlin, Hanna ;

Kapoor, Rajat ;

Shaefi, Shahzad ;

Melamed, Michal L. ;

Sutherland, Anne ;

Radbel, Jared ;

Green, Adam ;

Garibaldi, Brian T. ;

Srivastava, Anand ;

Leonberg-Yoo, Amanda ;

Shehata, Alexandre M. ;

Flythe, Jennifer E. ;

Rashidi, Arash ;

Goyal, Nitender ;

Chan, Lili ;

Mathews, Kusum S. ;

Hedayati, S. Susan ;

Dy, Rajany ;

Toth-Manikowski, Stephanie M. ;

Zhang, Jingjing ;

Mallappallil, Mary ;

Redfern, Roberta E. ;

Bansal, Amar D. ;

Short, Samuel A. P. ;

Vangel, Mark G. ;

Admon, Andrew J. ;

Semler, Matthew W. ;

Bauer, Kenneth A. ;

Hernan, Miguel A. ;

Leaf, David E. .

ANNALS OF INTERNAL MEDICINE, 2021, 174 (05) :622-+

[2] Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies [J].

Armstrong, R. A. ;

Kane, A. D. ;

Cook, T. M. .

ANAESTHESIA, 2020, 75 (10) :1340-1349

[3] Thromboinflammation and the hypercoagulability of COVID-19 [J].

Connors, Jean M. ;

Levy, Jerrold H. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) :1559-1561

[4] American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 [J].

Cuker, Adam ;

Tseng, Eric K. ;

Nieuwlaat, Robby ;

Angchaisuksiri, Pantep ;

Blair, Clifton ;

Dane, Kathryn ;

Davila, Jennifer ;

DeSancho, Maria T. ;

Diuguid, David ;

Griffin, Daniel O. ;

Kahn, Susan R. ;

Klok, Frederikus A. ;

Lee, Alfred Ian ;

Neumann, Ignacio ;

Pai, Ashok ;

Pai, Menaka ;

Righini, Marc ;

Sanfilippo, Kristen M. ;

Siegal, Deborah ;

Skara, Mike ;

Touri, Kamshad ;

Akl, Elie A. ;

Akl, Imad Bou ;

Boulos, Mary ;

Brignardello-Petersen, Romina ;

Charide, Rana ;

Chan, Matthew ;

Dearness, Karin ;

Darzi, Andrea J. ;

Kolb, Philipp ;

Colunga-Lozano, Luis E. ;

Mansour, Razan ;

Morgano, Gian Paolo ;

Morsi, Rami Z. ;

Noori, Atefeh ;

Piggott, Thomas ;

Qiu, Yuan ;

Roldan, Yetiani ;

Schuenemann, Finn ;

Stevens, Adrienne ;

Solo, Karla ;

Ventresca, Matthew ;

Wiercioch, Wojtek ;

Mustafa, Reem A. ;

Schuenemann, Holger J. .

BLOOD ADVANCES, 2021, 5 (03) :872-888

[5] Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS-CoV-2: A Retrospective Cohort Study [J].

Ferguson, John ;

Volk, Stacy ;

Vondracek, Thomas ;

Flanigan, John ;

Chernaik, Andrew .

JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (11) :1411-1415

[6] Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [J].

Goligher, Ewan C. ;

Bradbury, Charlotte A. ;

McVerry, Bryan J. ;

Lawler, Patrick R. ;

Berger, Jeffrey S. ;

Gong, Michelle N. ;

Carrier, Marc ;

Reynolds, Harmony R. ;

Kumar, Anand ;

Turgeon, Alexis F. ;

Kornblith, Lucy Z. ;

Kahn, Susan R. ;

Marshall, John C. ;

Kim, Keri S. ;

Houston, Brett L. ;

Derde, Lennie P. G. ;

Cushman, Mary ;

Tritschler, Tobias ;

Angus, Derek C. ;

Godoy, Lucas C. ;

McQuilten, Zoe ;

Kirwan, Bridget-Anne ;

Farkouh, Michael E. ;

Brooks, Maria M. ;

Lewis, Roger J. ;

Berry, Lindsay R. ;

Lorenzi, Elizabeth ;

Gordon, Anthony C. ;

Berry, Scott M. ;

McArthur, Colin J. ;

Neal, Matthew D. ;

Hochman, Judith S. ;

Webb, Steven A. ;

Zarychanski, Ryan ;

Ahuja, Tania ;

Al-Beidh, Farah ;

Annane, Djillali ;

Arabi, Yaseen M. ;

Aryal, Diptesh ;

Kreuziger, Lisa Baumann ;

Beane, Abi ;

Bhimani, Zahra ;

Bihari, Shailesh ;

Billett, Henny H. ;

Bond, Lindsay ;

Bonten, Marc ;

Brunkhorst, Frank ;

Buxton, Meredith ;

Buzgau, Adrian ;

Castellucci, Lana A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (09) :777-789

[7] Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study [J].

Helms, Julie ;

Severac, Francois ;

Merdji, Hamid ;

Schenck, Maleka ;

Clere-Jehl, Raphael ;

Baldacini, Mathieu ;

Ohana, Mickael ;

Grunebaum, Lelia ;

Castelain, Vincent ;

Angles-Cano, Eduardo ;

Sattler, Laurent ;

Meziani, Ferhat .

ANNALS OF INTENSIVE CARE, 2021, 11 (01)

[8] Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia [J].

Hsu, Andrew ;

Liu, Yuchen ;

Zayac, Adam S. ;

Olszewski, Adam J. ;

Reagan, John L. .

THROMBOSIS RESEARCH, 2020, 196 :375-378

[9] Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 A Systematic Review and Meta-analysis [J].

Jimenez, David ;

Garcia-Sanchez, Aldara ;

Rali, Parth ;

Muriel, Alfonso ;

Bikdeli, Behnood ;

Ruiz-Artacho, Pedro ;

Le Mao, Raphael ;

Rodriguez, Carmen ;

Hunt, Beverley J. ;

Monreal, Manuel .

CHEST, 2021, 159 (03) :1182-1196

[10] Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [J].